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Abstract
Background: Adult neurogenesis is a particular example of brain plasticity that is partially modulated by the 
endocannabinoid system. Whereas the impact of synthetic cannabinoids on the neuronal progenitor cells has been 
described, there has been lack of information about the action of plant-derived extracts on neurogenesis. Therefore we 
here focused on the effects of Δ9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) fed to female C57Bl/6 and 
Nestin-GFP-reporter mice on proliferation and maturation of neuronal progenitor cells and spatial learning 
performance. In addition we used cannabinoid receptor 1 (CB1) deficient mice and treatment with CB1 antagonist 
AM251 in Nestin-GFP-reporter mice to investigate the role of the CB1 receptor in adult neurogenesis in detail.
Results: THC and CBD differed in their effects on spatial learning and adult neurogenesis. CBD did not impair learning 
but increased adult neurogenesis, whereas THC reduced learning without affecting adult neurogenesis. We found the 
neurogenic effect of CBD to be dependent on the CB1 receptor, which is expressed over the whole dentate gyrus. 
Similarly, the neurogenic effect of environmental enrichment and voluntary wheel running depends on the presence 
of the CB1 receptor. We found that in the absence of CB1 receptors, cell proliferation was increased and neuronal 
differentiation reduced, which could be related to CB1 receptor mediated signaling in Doublecortin (DCX)-expressing 
intermediate progenitor cells.
Conclusion: CB1 affected the stages of adult neurogenesis that involve intermediate highly proliferative progenitor 
cells and the survival and maturation of new neurons. The pro-neurogenic effects of CBD might explain some of the 
positive therapeutic features of CBD-based compounds.
Background
The recreational use of cannabis is often justified by
extrapolation from the unquestionable physiological role
of endocannabinoids in brain function [1], and the suc-
cessful and beneficial manipulation of the endocannabi-
noid system for medical purposes [2,3] by plant extracts
from cannabis sativa or synthetic agonist and antagonists
specific for cannabinoid receptor1 or 2 (CB1, CB2) [4,5].
The abuse of cannabis can be associated with detrimental
long-term consequences, for example an increased risk of
developing memory impairments [6,7].
The process of generating new neurons throughout life
in the hippocampus probably plays a role in learning and
memory processes [8], and impairment of adult hip-
pocampal neurogenesis is thought to be part of the
pathogenesis of neurodegenerative disorders like demen-
tia, epilepsy and schizophrenia [9,10]. Adult neurogenesis
is a particular example of brain plasticity as it involves the
integration of entire cells [11,12]. Due to its physiological
role in brain plasticity the endocannabinoid system might
contribute to the control of adult hippocampal neurogen-
esis in health and disease. A number of arguments point
into the direction that cannabinoids might exert some of
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Page 2 of 14their actions via their effects on adult neurogenesis
(reviewed in [13]).
The therapeutic activities of cannabinoids include anal-
gesia, immuno-suppression, mood stabilization, anti-
emesis, bronchodilatation and neuroprotection [14].
Because of the psychotropic effects of some cannabi-
noids, their clinical use is limited. Cannabidiol (CBD) is
the main non-psychotropic compound of the plant can-
nabis sativa and belongs to the group of exogenous can-
nabinoids [15]. Due to its lack of psychoactive actions,
CBD represents one of the most promising candidates for
clinical application [14]. CBD was shown to act anti-psy-
chotic in Parkinson's disease and as a monotherapy in
treatment-resistant schizophrenia [16,17]. The neuropro-
tective effects of CBD have been linked with its antioxi-
dant activity [18]. Evidence emerges that CBD realizes
some of its effect via the classical CB receptors [19].
Many constituents of the endogenous cannabinoid sys-
tem like the CB1 and CB2 receptors and their endoge-
nous ligands Anandamide (AEA) and 2-
arachidonylglycerol (2-AG) as well as the AEA-degrading
enzyme fatty acid amide hydrolase (FAAH) and the 2-AG
synthesizing enzyme diacylglycerol lipases are found in
neuronal developmental and adult neurogenesis [20-22].
Several studies investigating the role of the cannabinoid
system in adult neurogenesis found that stimulation of
CB1 seemed to either increase or decrease adult neuro-
genesis [21,23]. For example, the synthetic agonist HU210
decreased the number of intermediate progenitor cells in
one study [24], but promoted neuronal differentiation in
another [25]. In other studies, CB1 receptor activation
promoted precursor cell proliferation and the generation
of neurospheres ex vivo, which was abrogated in CB1-
deficient precursor cells, and proliferation of hippocam-
pal precursor cells was increased in FAAH deficient mice
[21,23,26]. Likewise, in adult CB1-deficient mice, neural
progenitor proliferation is decreased. In addition, endo-
cannabinoid signaling controls neural progenitor differ-
entiation in the adult brain by promoting astroglial
differentiation of newly born cells [23]. Along the same
line, Rueda et al. have shown that the endocannabinoid
AEA inhibited neuronal progenitor cell differentiation
through attenuation of the extracellular signal regulated
kinase pathway in vitro, and that adult neurogenesis in
the dentate gyrus was significantly decreased by the AEA
analogue methanandamide and increased by the CB1
antagonist SR141716 [27].
Precursor cell proliferation is a relatively non-specific
measure of neurogenesis and not identical to the net pro-
duction of new neurons. Progenitor cell proliferation is,
for example, increased after epileptic seizures without
necessarily leading to functional neurogenesis [28]. The
incorporation of the progenitor cell into the neuronal
network is impaired after seizures despite a high prolifer-
ation rate [29]. In the study by Jin et al. only BrdU incor-
poration was measured without further phenotyping the
labeled cells and only cell proliferation was directly
addressed [30]. However, they reported increased cell
proliferation after treatment with CB1 antagonists
SR141716 and AM251, which is in line with the findings
by Rueda at al. [27]. In addition, they showed that
SR141716 enhances cell proliferation via the vanillin
receptor 1 [30]. The absence of the CB1 receptor resulted
again in decreased proliferation.
The confusion that emerges when comparing the stud-
ies could be explained by differences in the study design,
compounds used, sex of the animals, duration of applica-
tion, and the readout parameters for "adult neurogenesis".
Moreover, in the context of adult neurogenesis, only syn-
thetic compounds interacting with the endogenous can-
nabinoid system have been investigated so far. It has been
speculated that also plant-derived cannabinoids might
have an impact on neurogenesis, but no data exist to date.
The sole exception is a brief study reporting no effects on
cell proliferation in general [31].
In our study we therefore first examined the effects on
adult neurogenesis in female C57Bl/6 mice by pharma-
ceutical extracts enriched with Δ9-tetrahydrocannabinol
(THC) or Cannabidiol (CBD) directly derived from the
plant cannabis sativa. Since THC's and CBD's mode of
actions are partly CB1-dependent [19,32], we then looked
at the time course (including proliferation and net-neuro-
genesis) of the maturation process of neuronal precursor
cells in CB1-/- C57Bl/6 female mice and the impact of the
CB1 antagonist AM251.
Results
Chronic THC treatment impairs spatial learning
Either THC- or CBD-enriched or control (CTR) diet was
fed to female C57Bl/6 or Nestin-GFP-reporter mice. The
food intake and the weight gain over the period of 6
weeks were similar in all the treatment groups (see addi-
tional file 1, Additional file 2). To examine the impact of
chronic THC vs. CBD treatment on spatial memory, we
tested the three experimental groups (THC, CBD, CTR)
in the Morris water maze (MWM). The task in the MWM
is to navigate to a hidden platform using spatial cues in
the room. As shown in figure 1A, THC mice were slower
in finding the hidden platform over the whole acquisition
period (repeated measures ANOVA, F2,20 = 3.49; p =
0.0014). In addition, THC mice showed a significantly
impaired performance during the reversal learning (with
the hidden platform at a new position) with regard to
both latency (THC: 36.13 +/- 10.94, CTR: 16.88 +/- 4.21,
p = 0.002, ANOVA, F2,20 = 3.49, Fig. 1A) and distance to
platform (THC: 49.4 ± 6.76, CTR: 31.93 ± 2.94, p = 0.002,
Wolf et al. Cell Communication and Signaling 2010, 8:12
http://www.biosignaling.com/content/8/1/12
Page 3 of 14ANOVA, F2,20 = 3.49; Fig. 1B). All three groups per-
formed at the same level when the platform was made
visible on day 6 to test for possible visual impairments
and the general ability to perform the task (Fig. 1A, B).
The impaired learning performance of the THC-treated
mice was also reflected by the shorter time the animals
spent in the old target quadrant and target zone during
the probe trial at day 4 (Fig. 1C). A rotarod test to assess
general locomotor functions and fitness was performed
on day 7. The THC group performed better than CTR
(CTR 138.47 ± 25.844 s, THC group 180.82 ± 26.17 s; p =
0.0046, ANOVA, F2,16 = 3.634; Fig. 1C), whereas CBD
performed at control level. Therefore, the decreased per-
formance of THC mice in the water maze could not be
attributed to a reduced general fitness.
CBD mice showed some (statistically not significant, p
= 0.124; F2,20 = 3.49; Fig. 1A, B) impairment during acqui-
sition. During the probe trial (Fig. 1C) and the reversal
they performed very similar to CTR.
Chronic THC treatment decreases adult neurogenesis
We have previously reported that adult hippocampal
neurogenesis can be linked to aspects of the acquisition
phase during water maze learning [33] with a particular
contribution to reversal performance [34,35]. We did not
find a specific reversal phenotype in the present study but
nevertheless asked whether a decrease in adult neurogen-
esis, possibly matching the observed alterations in water
maze performance, might be found after THC or CBD
treatment.
We found that chronic THC application reduced pre-
cursor cell proliferation in the DG (THC vs. CTR: 2018 ±
96; 2515 ± 180; n = 5; p = 0.037, Fig. 2A) without affecting
cell survival or net neurogenesis. In contrast, however,
despite decreasing proliferation, CBD increased cell sur-
vival (proliferation: CBD vs. CTR: 2083 ± 102 vs. 2515 ±
180; n = 5; p = 0.0358; survival: CBD vs. CTR: 756 ± 28
vs.180 ± 21; n = 5; p = 0.0012; Fig. 2A).
In both, THC and CBD groups we found a minimal
reduction in the number of BrdU-labeled type-1/2a cells,
i.e. Nestin-GFP-positive, Doublecortin (DCX)-negative
cells, but a significant reduction at the level of the type-2b
cells (Nestin-GFP-positive, DCX-positive; THC vs. CTR:
502 ± 83 vs. 748 ± 78; n = 5; p = 0.028; CBD vs. CTR: 507
± 62 vs. 748 ± 78; n = 5; p = 0.032; Fig. 2B). In THC the
number of DCX-positive/Nestin-GFP-negative cells was
also reduced (THC vs. CTR: 113 ± 19 vs. 249 ± 26; n = 5;
p = 0.004; Fig. 2B), possibly indicating that THC might
not increase net neurogenesis but nevertheless accelerate
the transition through the DCX-positive stage. For an
overview of the maturation stages see below. A represen-
tative BrdU/NeuN staining is shown in figure 2C.
There was, however, a significant increase in the pro-
duction of BrdU/NeuN-positive cells in the CBD group
(CBD vs. CTR: 297 ± 32 vs.146 ± 23; n = 5; p = 0.001; Fig.
2A, B), suggesting that in this case an accelerated transi-
tion through the DCX stage might result in more neu-
rons, an effect absent in the case of THC.
Taken together THC treated mice showed reduced
water maze performance, albeit not the presumably neu-
rogenesis-related reversal impairment, and reduced adult
neurogenesis, whereas CBD mice did not. On the other
hand our results pointed to a positive effect of CBD on
adult neurogenesis that we now intended to explore fur-
ther.
Figure 1 Spatial learning was impaired after THC treatment. C57Bl/6 female mice were either fed with food supplemented with THC-rich or CBD-
rich plant extracts or a control diet. Spatial memory was tested after 6 weeks of treatment. THC mice were slower in finding the hidden platform over 
the whole acquisition period and during the reversal learning, with regard to both latency (A) and distance (B) to platform. All three groups performed 
at the same level when the platform was made visible on day 6 to test for possible visual impairments and the general ability to perform the task. A 
Rotarod test to measure general locomotor function and fitness was performed on day 7. The THC group performed better than CTR (C); * p ≤ 0.05.
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mice
We next asked whether these CBD-mediated effects on
BrdU incorporation might be mediated by the CB1 recep-
tor, which is highly expressed in the dentate gyrus and fed
CBD to CB1-/- mice and their wild type litter mates in
parallel for 6 weeks. We found that the increase in BrdU
cell survival induced by CBD was abolished in CB1-/-
mice (Fig. 3; WT/CBD vs. CB1-/-/CBD: 716 ± 83 vs.152 ±
28; n = 5; p = 0.001). CB1-/- mice showed a decrease in
the number of BrdU cells. This decrease in CB1-/- has
already been described in the literature. But we could
here show a similar effect of CB1-/- at the survival time
point at 4 weeks after BrdU application (CB1-/- vs. WT:
180 ± 15 vs.368 ± 21; n = 5; p = 0.002).
CB1 is expressed during the DCX-stage of adult 
hippocampal neurogenesis
Given this relevance of the CB1 receptor for the observed
adult neurogenesis phenotype we next asked, which cells
would express the CB1 receptor in the course of adult
neurogenesis. We used hippocampal sections from
untreated female Nestin-GFP-reporter mice. Based on
these mice we have previously proposed a model of neu-
ronal development in the adult hippocampus [36-38].
Figure 3 CBD effect was absent in CB1-/- mice. We fed additional 
wild type and CB1-/- mice with CBD for 6 weeks. We found that the in-
crease in cell survival induced by CBD was abolished in CB1-/- mice; * p 
≤ 0.05.
Figure 2 CBD treatment enhanced adult neurogenesis. BrdU cells 
reflect the population of proliferating cells at a given period of time. 
Proliferation was measured 24 h after BrdU injection, while survival was 
measured 4 weeks after BrdU injection. NeuN/BrdU double positive 
cells at 4 weeks after BrdU injection are the neurons that were gener-
ated and survived during the period of 4 weeks. THC treatment for 6 
weeks reduced cell proliferation without affecting neuronal survival. In 
contrast, CBD treatment decreased proliferation as well, but increased 
neuronal cell survival seen at 4 weeks after BrdU injection. (A). Animals 
expressing Nestin, an early marker of neuronal maturation, under a GFP 
promotor were also fed with THC-rich, CBD-rich, or control (CTR) diet 
for 6 weeks. The animals were assessed at 7 days after BrdU injection to 
evaluate the early stages of neurogenesis. In both THC and CBD groups 
we found a minimal reduction in the number of BrdU-labeled type-1/
2a cells (Nestin-GFP-positive, DCX-negative) but a significant reduction 
on the level of the type-2b (Nestin-GFP-positive, DCX-positive). In THC 
the number of DCX-positive/Nestin-GFP-negative cells was also re-
duced. There was a significant increase in the production of BrdU/
NeuN-positive cells in the CBD group (B); * p ≤ 0.05. In (C) we show a 
representative micrograph of BrdU labeled cells (red) within the gran-
ule cell layer labeled with NeuN (blue) of the dentate gyrus. The section 
is one out of nine throughout one hippocampus of a female C57Bl/6 
animal that received 3 BrdU injections 4 weeks prior to analysis. The 
section is 40 μm thick and the scale bar is 50 μm.
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cell (type-1) development proceeds over a population of
highly proliferative Nestin-GFP-positive intermediate
progenitor cells with glial properties, but lacking the
radial morphology (type-2a) and a similarly proliferative
progenitor cell which is still Nestin-GFP-positive but also
expresses DCX (as well as, for example, Prox1 and
NeuroD1) and thus shows signs of neuronal determina-
tion (type-2b). Migratory, neuroblast-like type-3 cells are
DCX-positive but do not express Nestin-GFP anymore.
They show limited proliferation. After this stage, cells go
through a postmitotic maturation stage, during which the
new neurons extend their neurites and which is associ-
ated with the transient expression of Calretinin [37,39]
and of the lasting postmitotic neuronal marker NeuN.
Based on this model of adult hippocampal neurogene-
sis and the sequence of cellular morphology and marker
expression, we found CB1-receptor expression spread
over the entire dentate gyrus and the whole course of
neurogenesis (Fig. 4A). However, it appeared that com-
paratively less staining was observed in the population of
Nestin-positive type 1 cells (Fig. 4B) and type 2a cells.
However, there was a tendency towards a stronger signal
in cells expressing DCX (type 2b/3 cells; Fig. 4C, D), post-
mitotic new neurons that express Calretinin (Fig. 4E, F)
and NeuN-positive mature new neurons (Fig. 4G, H).
This implies that CB1 expression would increase with the
degree of differentiation from type-2b cells onwards.
CB1 mRNA expression is induced by activity
We subjected adult untreated female C57Bl/6 mice to
either voluntary wheel running (RUN) or enriched envi-
ronment (ENR). One group was housed in conventional
cages (CTR). Type-2 cells are highly regulated cells in vivo
and are influenced by behavioral activity. We have previ-
ously shown that both environmental enrichment and
voluntary physical activity induce adult hippocampal
neurogenesis while having differential effects on the type-
2 progenitor cells [40]. We here confirmed this observa-
tion at the level of Nestin-mRNA expression, showing
that RUN but not ENR increased Nestin mRNA (Fig. 5C
CTR vs. ENR: 8 ± 2.2 vs. 6 ± 1.7; n = 6; p = 0.214; CTR vs.
RUN: 8 ± 2.2 vs.13 ± 5.1; n = 6; p = 0.041). These findings
are consistent with the counts of BrdU positive cells (Fig.
5A CTR vs. ENR: 1184 ± 81 vs.1462 ± 35; n = 5; p = 0.051;
CTR vs. RUN 1184 ± 81 vs. 2197 ± 94; n = 5; p = 0.002). In
the same samples, we found that both RUN and ENR
increased the expression of CB1 receptor mRNA in the
hippocampus (Fig. 5C; CTR vs. ENR: 4 ± 1.8 vs.10.5 ± 0.8;
n = 6; p = 0.0001; CTR vs. RUN: 4 ± 1.8 vs. 12.5 ± 1.6; n =
6; p = 0.0001). This supported our result from immuno-
histochemistry with regard to the expression of CB1 on
neuronal progenitor cells. We next wanted to know,
Figure 4 Cannabinoid receptor 1 immunoreactivity in the den-
tate gyrus. We here show representative photomicrographs of immu-
nofluorescent staining of 40 μm thick mouse brain sections. CB1 
immunoreactivity appears in red, Nestin-GFP in green, DCX, Calretinin 
(CR) and NeuN in Blue. The confocal scanning photomicrograph, 1 μm 
thickness, 40× magnification, shows that the CB1 receptor (red) is 
highly expressed in the dentate gyrus (A). The three-dimensional re-
construction of z-series of 8 confocal scanning photomicrograph (1.5 
mm each) in shown in (B). The co-localization with Nestin-GFP (green) 
was found in some of cells with rounded morphology, less in the radial 
glia-like type-1 cells as shown in detail using orthogonal projections. 
The projection of 11 (C) and 13 (D) confocal scanning micrographs (1,5 
μm thickness) reveals that DCX-positive cells (blue) show co-localiza-
tion with the CB1 receptor (red). The 113× magnification shows in 
more detail the expression of CB1 receptor in DCX-positive cells (D). 
The confocal scanning photomicrograph, 1 μm thickness, magnifica-
tion 40× shows a co-localization of Calretinin-positive staining with 
CB1 receptor (E). The three-dimensional reconstruction of z-series of 6 
confocal scanning photomicrographs (1.5 mm each), 113× magnifica-
tion show that Calretinin-positive cells (blue) are surrounded by CB1 
receptor (red). The three-dimensional reconstruction of z-series of 13 
(G) and 9 (H) confocal scanning photomicrographs (1.5 μm each) show 
immuno-reactivity to CB1 (red) in NeuN (blue) cells. The 113× magnifi-
cation shows the co-localization in more detail (H). The representative 
scale bar is in G (50 mm) for A, C, E, and G; it is in H (20 mm) for B, D, F, 
and H.
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sary to elicit the effects of RUN and ENR on adult neuro-
genesis
Activity-induced neurogenesis is absent in CB1-/- mice
We next subjected female CB1-/- mice and their litter-
mates to voluntary wheel running (CB1-/-/RUN and WT/
RUN) for 10 consecutive days. We found that voluntary
wheel running did not increase cell proliferation in CB1-/-
mice as it did in WT mice. CB1-/- mice however, showed
an increased baseline proliferation consistent with the
findings presented in figure 6A (Fig. 5A; WT/CTR vs.
CB1-/-/CTR: 1184 ± 81 vs. 2251 ± 118; n = 5; p = 0.002;
WT/RUN vs. CB1-/-/RUN: 2197 ± 74 vs. 1772 ± 68; n = 5;
p = 0.018). ENR primarily affects cell survival. In CB1-/-
mice the ENR-induced increase in cell survival was abol-
ished (Fig. 5B; WT/ENR vs. CB1-/-/ENR: 553 ± 14 vs. 362
± 42; n = 5; p = 0.023). Taken together both results sug-
gest that CB1-mediated mechanisms play an important
role in mediating the behavior-induced regulation of
adult hippocampal neurogenesis.
Proliferation is increased but neurogenesis is reduced in 
CB1-/- mice
We now returned to evaluation of CB1 effects during the
course of adult neurogenesis and how the affected neu-
ronal maturation stages are influenced via the cannabi-
noid-mediated pathway. We therefore conducted a time-
course study in female untreated CB1-/- mice compared to
littermate controls (WT). At 24 h after BrdU the number
of BrdU-positive cells was higher in the mutant mice
(WT vs. CB1-/-: 2175 ± 32 vs. 2489 ± 27; n = 5; p = 0.0042;
Fig. 6A) but was lower at 4 weeks after BrdU (WT vs.
CB1-/-: 368 ± 21 vs.180 ± 15; n = 5; p = 0.0024; Fig. 6A).
The percentage of NeuN-positive cells was also lower at 4
weeks after BrdU resulting in a net reduction of adult
neurogenesis in the mutants (WT vs. CB1-/-: 82% vs. 66%;
n = 5; p = 0.048; Fig. 6A). When we looked at 24 h we
found a relative reduction in the number of proliferative
DCX-positive cells in the knock out animals (WT vs.
CB1-/-: 81% vs. 75%; n = 5; p = 0.063; Fig. 6A). The contri-
bution of type-2 cells to the increase in proliferation in
CB1-/- mice could not be further elucidated. GFAP-posi-
tive cells largely accounted for the initial increase in pro-
liferation (WT vs. CB1-/-: 6% vs. 20%; n = 5; p = 0.001; Fig.
6A). Additional studies will have to investigate to what
degree these GFAP-positive cells include the radial glia-
like type-1 cells. At an intermediate point in time at 7
days after BrdU injection, the proliferation in CB1-/- ani-
mals was strongly reduced compared to controls, leading
to the later reduction in adult net neurogenesis at 4 weeks
after BrdU injection (WT vs. CB1-/-: 1683 ± 65 vs. 836 ±
19; n = 5; p = 0.002; Fig. 6A).
Figure 5 Activity induced effects. Running is known to enhance pro-
liferation of cells in the dentate gyrus while enriched environment has 
a stronger effect on neuronal survival. We found that while RUN in-
creased cell proliferation in WT mice, this was not the case in CB1-/- 
mice. CB1-/- mice showed an increased baseline proliferation (A). In 
CB1-/- ENR-induced increase in cell survival was abolished. (B) Both 
housing conditions resulted in an increase of CB1-mRNA in the hip-
pocampus of wild type mice. The early neuronal marker Nestin was 
only increased in the RUN paradigm (C); * p ≤ 0.05.
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of DCX-positive precursor cells and reduces further 
differentiation
These observations suggested that CB1-activity stimu-
lates neurogenesis in particular from type-2 cells onward,
especially affecting the DCX-positive populations by
accelerating development and promoting survival. To fur-
ther study this shift from reduction to stimulation, which
is already apparent in the time-course depicted in Fig. 6A,
we conducted another experiment in untreated adult
female Nestin-GFP-reporter mice to identify effects of
CB1 antagonist AM251 on the intermediate precursor
cell stages.
At 1 h after BrdU application counts of BrdU-positive
cells reflect S-phase entry. As expected, AM251-treat-
ment increased the number of BrdU-positive cells com-
pared to vehicle controls (vehicle vs. AM251: 1142 ± 28
vs. 1674 ± 27; n = 5; p = 0.038; Fig. 6B). At 24 h the num-
bers had roughly doubled, reflecting a completed cell
cycle. The relative difference between the groups was
maintained at this point in time, confirming that CB1
receptor activity reduced cell proliferation from prevent-
ing S-phase entry onward (vehicle vs. AM251: 2810 ± 35
vs. 4048 ± 120; n = 5; p = 0.0042; Fig. 6B). Phenotypic
analysis revealed that this increase was largely accounted
by type-2b cells, whereas type-2a was even reduced (vehi-
Figure 6 Effects of CB1 absence on neuronal maturation. By using animals at different points of time after BrdU injection a detailed time course 
of neuronal maturation has been established. At 24 h after BrdU the number of BrdU-positive cells was increased in the mutant mice but at 4 weeks 
the number of BrdU-positive cells was reduced compared to the controls. The percentage of NeuN-positive cells was also reduced resulting in a net 
reduction of adult neurogenesis in the mutants. When we looked at the 24 h time point we found a relative reduction in the number of proliferative 
DCX-positive cells At an intermediate 7d time point, the increased proliferation in CB1-/- animals had yielded to a strong reduction in BrdU positive 
cells compared to controls (A). To investigate early stages of neuronal maturation, we used Nestin-GFP-reporter mice and injected the CB1 antagonist 
AM251. At 1 h after BrdU application counts of BrdU-positive cells reflect S-phase entry. AM251-treatment increased the number of BrdU-positive cells 
compared to vehicle controls. At 24 h the numbers had roughly doubled, reflecting a completed cell cycle. Phenotypic analysis revealed that this in-
crease was largely accounted by type-2b cells and later DCX-positive cells, whereas type-2a was even reduced. At 48 h control values for BrdU began 
to be higher than in the AM251-treated mice, leading to an almost two-fold reduction in AM251-treated mice at 7d (B); * p ≤ 0.05.
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type-2a 27% vs. 12%; n = 5; p = 0.024; Fig. 6B).
At 48 h AM251 values for BrdU began to be lower than
in the vehicle-treated mice (vehicle vs. AM251: 3182 ± 62
vs. 2035 ± 78; n = 5; p = 0.028; Fig. 6B), leading to an
almost two-fold reduction in AM251-treated mice at 7d
(Fig. 6B; vehicle vs. AM251: 1627 ± 18 vs. 567 ± 15; n = 5;
p = 0.023). Most likely the BrdU positive cells in later
maturation stages (depicted as "other") mainly account
for the decrease (vehicle vs. AM251: other 3% vs. 0.5%; n
= 5; p = 0.002; Fig. 6B).
Discussion
In this study we have found substantial differences
between THC and CBD treatment, supporting the previ-
ously reported disruption of memory formation by THC
[41]. We did not find a suggestive association between
CBD-mediated CB1 activity, learning performance in the
water maze, and adult hippocampal neurogenesis. THC
impaired cognitive and enhanced locomotor function but
had no effect on neurogenesis, when given chronically.
The learning phenotype in the Morris water maze did not
correlate with the neurogenesis phenotype. Taken
together, both THC and CBD effects on this type of hip-
pocampus-dependent function cannot be linked to adult
neurogenesis in a straightforward way. This discrepancy
between functional and cellular hippocampal features
had not yet been shown for THC or CBD, but the phe-
nomenon of divergence between learning paradigms and
neurogenesis is known from other studies (reviewed in
[42]). When neurogenesis was blocked by focal x-radia-
tion the mice that had been exposed to an enriched envi-
ronment still performed better in the Morris water maze
than the mice housed in standard cages. Since enriched
environment enhances the survival of newly generated
neurons, the investigators claimed separate effects of the
enriched environment on neurogenesis and on spatial
learning [43]. Other groups showed that hippocampal
irradiation immediately before the test had no effect,
while irradiation days before the test impaired long-term
memory in the water maze, indicative of a critical time
window [44].
We showed that CBD increased neurogenesis at the
survival stage 4 weeks after BrdU injection. Similar to the
neuronal survival effect of CBD it has been reported, that
the synthetic non-selective cannabinoid agonist WIN-
55,212-2 restored the physiologically decreased levels of
adult neurogenesis in aged rats [45]. In the current study
we have studied young adult mice, but it might be worth-
while to investigate in further studies the CBD effect in
aged animals. CBD is known to be beneficial in schizo-
phrenia or schizophrenic-like behaviour [17], where
patients show a decrease in hippocampal volume and
neurogenesis might be impaired [17,46]. CBD has some
antipsychotic properties [47]. Moreover, smoking some
strains of cannabis containing relatively more CBD, in
addition to THC, appears to be more protective against
the psychotic symptoms induced by THC alone [48].
A study by Boucher et al. has shown that THC impaired
spatial memory and reversal learning, even in animals
that received a THC pretreatment, indicating that
although tolerance to the effects of THC on neuronal
activity in the prefrontal cortex was reported, cannabi-
noid-induced memory impairment in these animals per-
sisted [7]. Although we could only test our animals at one
time point, including the information of tolerance resis-
tance to THC from the reference mentioned above makes
us confident that no acute or tolerance effects were pres-
ent during our testing phase.
Taken together, the findings suggest diverse effects of
the cannabinoid system on memory and cellular plastic-
ity. These effects cannot be plainly categorized into
impairing or enhancing effects of cannabinoid activation
or deactivation [49]. The same might be true for the find-
ing that THC increased the performance in the rotarod
test. CB1 activation in the cerebellum by intra-cerebellar
THC injection led to locomotor deficits [50]. Moreover,
stimulation of cerebellar CB1 receptors with the agonists
CP55,940 and HU-210 impaired rotarod performance
[51]. THC injected intraperitoneally on the other hand
failed to provoke motor coordination disturbances in
wild type B6/CBA mice [52]. The route of administration
seems to be a key difference between this one and the
other studies. CB1 receptors were activated in all relevant
brain regions and the local concentration of THC in a
given brain structure was lower than when administered
directly into the cerebellum [52]. In our study the mice
took up the THC via the food, which led to improved
rotarod performance. In the light of therapeutically tar-
geting locomotor dysfunction with cannabinoids this
finding might be notable. The therapeutic potential of the
cannabinoids was also investigated in neurological dis-
eases such as multiple sclerosis, Gilles de La Tourette
syndrome, Parkinson and Huntington disease that all
include locomotor disabilities [53]. Although the efficacy
was not always clearly established, the undesirable effects
observed were generally mild and well tolerated [54]. The
drugs used to treat symptoms of multiple sclerosis
(Sativex, contains THC and CBD) failed to change the
neuropathological hallmarks of the disease. Patients
reported only minor changes in memory loss, while
improvements in locomotor and spasticity and neuro-
pathic pain were dominant [55]. Experiments with THC
and CBD in different concentrations might help to
unravel the complex pattern of such treatments and
should, as our results suggest, include measures of adult
neurogenesis.
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animals. Although CBD has low affinity to CB1 and its
effects are often mediated via non-CB receptors (e.g. the
vanilloid receptor) at least three other studies support
that cannabidiol effects were CB1 receptor-dependent
[19,56,57]. It might not be the only or usual mode of
action, but with regard to enhanced adult hippocampal
neurogenesis, CBD at least partially acts through the CB1
receptor. This result prompted us to investigate CB1
dependent regulation of neurogenesis utilizing CB1
receptor knock out animals as well as the CB1 receptor
antagonist AM251 in Nestin-GFP-reporter mice.
In female CB1-/- mice on a C57BL/6 background we
found increased proliferation 24 h after BrdU injection
and decreased net-neurogenesis (7 days and 4 weeks after
BrdU injection). Jin and colleagues reported impaired
progenitor cell proliferation in CB1-/- mice but found con-
tradicting increases with pharmacological CB1 antago-
nists SR141716A and AM251 [30,58]. We did not
observed such discrepancy. The time point of analysis in
the Jin et al. study was 3 days after BrdU injection. Thus,
they might not have detected the most acute effects.
Using the same compound AM251 on wild type mice, we
got different results at 7 days after BrdU injection.
Although we observed an increase of BrdU-labeled cells
at 1 h and 24 h, which would be in line with the findings
by Jin et al., we found a decrease in BrdU-labeled cells at
48 h and 7 days. When phenotyped, DCX-positive cells
accounted for the increase in proliferation at early time
points, but at late time points fewer DCX- and more Nes-
tin-positive cells were present indicating that maturation
was impaired at the DCX-stage. This supports our data,
that CB1 stimulation or blockage had different effects on
neuronal progenitor proliferation and differentiation or
maturation. The same pro-proliferative effect of AM251
at 24 h after BrdU injection have also been observed by
Hill et al. in rats [59].
One notable difference between the study of Jin et al.
and other studies (including ours) was their use of a CB1-
/- strain bred onto the CD1 background [60]. We have
previously shown that CD1 show a very unusual pattern
of baseline adult neurogenesis. Despite lower levels of
proliferation compared to C57BL/6 they actually achieve
high levels of net neurogenesis since survival exceeds any
other strain investigated so far [61]. Another difference
between the studies might have been the use of male vs.
female mice since a recent report demonstrated differ-
ences in CB1 receptor abundance in the hippocampus
between female and male mice [62]. Unfortunately Jin et
al. did not report the gender examined in their studies.
On the other hand, receptor abundance per se does not
allow strong conclusions about receptor activity.
In addition, we show that the time point of measure-
ment is critical when assessing the effects of the antago-
nists. Our findings imply, that CB1 receptor activity
would increase proliferation of type-1/2a, reduce prolif-
eration of type-2b/3 but accelerate maturation from these
cells and lead to a net reduction of adult neurogenesis.
Consequently, the increase observed in the Jin et al. study
after 3 days of AM251 in parallel to 3 days of BrdU is
likely to actually reflect a mix of increases and decreases,
which can only be untangled with a different BrdU injec-
tion protocol and a distinction of the different precursor
cell types.
CB1 receptors are expressed in the course of neuronal
development but they are present on all precursor cells,
beginning with the radial glia-like type-1 cells [23]. CB1
expression appears to increase with differentiation, an
observation that has also been made in embryonic corti-
cal development [63]. Together with our previous data on
wild type mice [40] these data indicate that CB1 is
expressed by cells that are primarily affected by activity-
dependent regulation of adult hippocampal neurogene-
sis. We could consequently show that this type of regula-
tion is impaired, if the CB1 receptor is absent. Keeney at
al. have shown that the CB1 antagonist Rimonabant
(SR141716) decreased running activity in C57Bl/6 female
mice when injected for 9 consecutive days at the peak of
running [64]. The situation in the knock out animal in
our study is different, since CB1 is absent constitutively
and not only at the peak of running like in the Keeney et
al. study. It is also notable that SR141716 has different
effects on neurogenesis than the absence of CB1 [30]. We
measured running performance as the distance run per
day for 10 consecutive days. As long as running the same
distance is indicative of a similar stimulus for neurogene-
sis, the conditions should have been the same for CB1-/-
and wild type mice. In the hippocampus of wild type mice
we found an upregulation of CB1 receptor mRNA in the
ENR and RUN mice along with an increase in Nestin
mRNA only in the RUN paradigm. This is in line with
studies reporting an increase in density of CB1 receptors
in the hippocampus after voluntary wheel running. When
AM251 was administered, activity-induced neurogenesis
was impaired [65]. This result also supports our findings
that activity-induced neurogenesis is absent in CB1-/-
mice. In contrast, a study using male mice that ran over a
period of 6 weeks, CB1-/- animals covered less distance
but showed greater numbers of DCX-expressing cells in
the dentate gyrus indicating that a running-phenotype
can be discovered after a prolonged running period [66].
Another study reported that CB1 receptor sensitivity in
the striatum increased after voluntary wheel running
[67]. In the light of therapeutic interventions targeting
the cannabinoid system, increasing the receptor by sim-
ple running might be of interest.
The putative contribution of new neurons to hip-
pocampal function has recently become increasingly
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(temporal separation, contextual integration, flexibility of
relearning, and integration of novelty) [34,68,69] have
been linked and a role in affective behavior has been
described [70,71]. Jiang and colleagues have suggested
that the CB1-mediated effects of HU210 on adult neuro-
genesis might have anxiolytic and anti-depressant-like
consequences [25]. It might thus be that the cannabinoid-
dependent regulation of adult neurogenesis is more rele-
vant for the emotional than for the cognitive aspects of
hippocampal function.
Conclusions
In this study we have shown that (1) exogenous cannabi-
noids THC and CBD differ in their effects on spatial
learning and adult neurogenesis. (2) CBD did not impair
learning but increased adult neurogenesis despite (3) a
CBD-induced reduction in cell proliferation. We found
(4) the pro-neurogenic effect of CBD to be dependent on
the CB1 receptor, which (5) shows a widespread expres-
sion over the entire dentate gyrus, including the neuronal
precursor cells. Similarly, (6) the pro-neurogenic effect of
environmental enrichment and voluntary wheel running
depended on the presence of the CB1 receptor. Along the
same line, (7) voluntary wheel running increased CB1
receptor mRNA in the hippocampus. We observed that
(8) in the absence of CB1 receptors, cell proliferation was
increased and neuronal differentiation reduced.
Although it has been reported that CBD binds with a
low affinity to the CB1 receptor, its mode of action on
neurogenesis seems to involve the CB1 receptor since
CBD had no effect on CB1-/- animals. This prompted us
to investigate the CB1 dependent regulation of neurogen-
esis using a genetic model and an antagonist. Taken
together, our results indicate that the CB1 receptor
appears to play an important role in modulating adult
hippocampal neurogenesis. More specifically, CB1 affects
the stages of adult neurogenesis that involve intermediate
highly proliferative progenitor cells (type-2 and type-3
cells) and the survival and maturation of the new neu-
rons. While these results are mostly in line with previous
results on CB1 function in adult neurogenesis (reviewed
in [13]), they also go beyond what was known since our
data elucidate the time-course of this action and reveal a
contribution of CB1 to activity-dependent regulation.
Although others and we found CB1 receptor expression
on precursor cells, the effects on cannabinoids on neuro-
genesis might still be indirect as well.
Materials and methods
Animals
The generation of CB1-/- mice on a C57Bl/6 background
has been described elsewhere [72]. The animals were
kindly provided by Roland Martin, National Institutes of
Health, Bethesda. The control group consisted of age-
matched littermates. Since we carried out heterozygote
breeding, we genotyped the progeny by PCR using the
following primers
3'AAGAACGAGATCAGCAGCCTCTGTT5';
3'GGATTCAGAATCATGAAGCACTCCA5'.
The experiments measuring the early stages of neuro-
genesis were performed in transgenic mice expressing the
green fluorescent protein (GFP) driven by regulatory ele-
ments of the Nestin gene, Nestin-GFP mice [73].
All the animals were held in the same room with a con-
sistent 12-hour-light-dark-cycle and were fed with the
standard or supplemented food and water ad libitum. To
estimate the daily food intake, animals and food were
weighted every 3rd day for the whole period of the experi-
ment (see additional file 1, 2).
All applicable local and federal regulations on animal
welfare were followed. The animal protocol was approved
by "Landesamt für Arbeitsschutz, Gesundheitsschutz und
technische Sicherheit Berlin (LaGetSi)".
Experimental design
Thirty female CB1-/- and their littermates (WT) mice
were randomly assigned to either enriched (CB1-/-/ENR;
WT/ENR) or standard housing (CB1-/-/CTR; WT/CTR)
or standard cages that were equipped with a running
wheel (CB1-/-/RUN; WT/RUN). RUN-assigned animals
had unlimited access to the running wheel (Tecniplast,
Hohenpeißenberg, Germany) for 10 days. The enriched
housing in which the animals lived for 4 weeks was simi-
lar to our previous studies [74]. Briefly, it consisted of a
spacious cage of approximately 80 × 80 cm floor area,
complemented with a re-arrangeable system of tubes, a
cardboard box house and a crawling ball. The ENR and
CTR animals were housed in groups of 5, in the RUN
cages 2 animals lived together. To evaluate CB1 mRNA
expression changes by activity, we subjected additional 5
female C57Bl/6 to either experimental condition (RUN,
ENR, CTR).
In a different set of experiments, 30 female wild-type
mice were housed in standard cages and fed with either a
diet supplemented with THC or CBD or without any
drug (CTR) for 6 weeks (chronic treatment). Ten CB1
knockout mice were fed with either a diet supplemented
with CBD or standard food.
After treatment 10 animals of each group were tested in
the Morris water maze for spatial memory performance
and in the rotarod for locomotor functions. All remaining
mice received daily intraperitoneal injections of Bro-
mdesoxyuridin BrdU (50 μg/kg body weight, Sigma) for
either 1 day or 5 consecutive days and were killed either
24 hours (proliferation) or 4 weeks (survival) after the last
BrdU injection. At the starting point of all experiments
the age was 6-8 weeks. The behavioral testing occurred 6
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when the testing started and 16 weeks when the survival
time point of adult neurogenesis was assessed.
To analyze the chronic impact of the cannabinoids on
the early stages of neuronal development, we utilized
transgenic animals where the Nestin promotor is linked
with an eGFP-construct emitting green fluorescence [73].
Twenty Nestin-GFP female animals were fed for 6 weeks
with a THC-rich or CBD-rich or standard diet (see
below). The antagonist AM251 compared to vehicle
injections (Torisolve, Tocris) was used on 10 Nestin-GFP-
reporter mice to evaluate the impact of CB1 at the early
stages of neurogenesis, as described previously [36]. In
parallel, five female CB1-/- and their littermates (WT)
each received BrdU for either 1 day or 5 consecutive days
and were killed either 24 hours (proliferation), 7 days or 4
weeks (survival) after the last BrdU injection
Cannabinoid and antagonist treatment
THC-rich or CBD-rich plant extract was kindly provided
by GW-Pharmaceuticals, UK. The plant extracts were
incorporated into a standard diet by ResearchDiet, USA
at the concentration of either 41.2% for active THC or
38.8% for active CBD. The diets were colour -labelled for
easier handling.
CB1 antagonist AM251 (Tocris) was injected intraperi-
toneally at 0.25 mg/kg in Tocrisolve (0.5 μg/μl in 100 μl
per animal).
Immunohistochemistry
Animals were deeply anesthetized with ketamine and
perfused transcardially with cold 4% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4. The brains were dis-
sected from the skulls and were postfixed overnight.
Before sectioning from a dry-ice-cooled copper block on
a sliding microtome (Leica, Bensheim), the hemispheres
were transferred to 30% sucrose in 0.1 M phosphate buf-
fer, pH 7.4, until they had sunk. Hemispheres were cut in
the coronal plane in 40 μm thick sections and cryo-pro-
tected. The level of generation of new cells was deter-
mined by the in vivo injection of BrdU, which
incorporates during the S-phase into the cell and thus
labelled proliferating cells. BrdU labelled cells in the sub-
granular zone of the dentate gyrus in the hippocampus
were quantified as described previously [69]. Briefly all
labelled cells per dentate gyrus were counted in every 6th
section containing the hippocampus. For each animal 9
sections have been counted (both sides). The number was
multiplied by six to estimate the total cell number per
brain. For BrdU staining, DNA was denatured in 2N HCL
for 30 minutes at 37°C. Free-floating sections were than
rinsed in 0.1 M borate buffer, pH 8.5, and thoroughly
washed in tris-buffered saline (TBS), pH 7.4. To block
endogenous peroxidase reactions, sections were pre-
treated with 0.6% H2O2. The rat-anti-mouse-BrdU anti-
body (Harlan Seralab) was diluted 1:500 in TBS supple-
mented with 0.1% TritonX-100, 0.1% Tween 20 and 3%
donkey serum (TBS-plus) and the sections were incu-
bated overnight at 4°C. After rinsing the sections in TBS
and a blocking step in TBS-plus, an incubation step with
the biotinylated secondary antibody (donkey-anti-rat,
Vector) diluted 1:500 in TBS-plus followed. ABC reagent
(Vectastain Elite, Vector Laboratories) was applied for 1 h
at a concentration of 9 μl/ml for each reagent. Diamin-
obenzidine (DAB, Sigma) was used as a chromogen at the
concentration of 0.25 mg/ml in TBS with 0.01% H2O2 and
0.04% nickelchloride followed by rinsing with tap water
and TBS. The sections were mounted on slides and cov-
erslipped with Neomount. To phenotype the proliferating
cells, we used triple staining for BrdU and a combination
of maturation markers as applicable. A total of randomly
selected 50 BrdU-positive cells per animal were pheno-
typed. Knowing the absolute number of BrdU cells in a
given brain, we were able to convert the percentage of
cells expressing one of the maturation markers and BrdU
into the absolute number of cells per phenotype in the
whole brain. All counting were done blinded by the same
researcher as described previously [38,69]. The primary
antibodies were applied in the following concentrations:
BrdU (1:500, Harlan Seralab), anti-Doublecortin (DCX,
1:200, Santa Cruz Biotechnologies), anti-Calretinin
(1:250, Santa Cruz), anti-GFP (to visualize Nestin, 1:500,
Swant), anti-NeuN (1:100, Chemicon), anti-GFAP (1:250,
Chemicon), anti-CB1 (1:250, LifeBioscience). Secondary
antibodies were anti-goat, anti-rabbit, anti-mouse, and
anti-rat (1:250, Jackson Laboratories) directly coupled to
a fluorochrome for confocal analysis. To test for statisti-
cal significant differences (p = 0.05) between two groups,
we used the non-parametrical Mann-Whitney-U-test.
RNA isolation and RT-PCR
RNA was isolated with an RNeasy mini isolation kit
according to the manufactures instructions (Qiagen,
Hilden, Germany). CB1 and Nestin content in 1 μg RNA
per sample was measured using the QuantiFast SYBR
Green RT-PCR Kit according to the manufactures
instructions (Qiagen, Hilden, Germany). We used the fol-
lowing primer pairs generated with primer3 software:
CB1: forward CTGGTTCTGATCCTGGTGGT, reverse
TGTCTCAGGTCCTTGCTCCT; Nestin: forward
TTGAGGCCTCCAGAAGAAGA, reverse GCCATCT-
GCTCCTCTTTCAC. The RNA amount was normalized
to the housekeeping gene GAPDH. Statistical analysis has
been done using the non-parametrical Mann-Whitney-U
test between two groups. PCR was performed using an
OPTICON II (BioRad, Munic, Germany).
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The Morris water maze (MWM) test is widely used to
test rodents for spatial memory performance [75]. We
followed the protocol revised by Wolfer and Lipp [76]. Six
trials of training, each maximally lasting 2 minutes, were
given each day. Latencies to reach the platform and swim
paths were recorded with an automatic video tracking
system (Ethovision, Noldus, Utrecht, Netherlands).
Animals were exposed to the MWM that contained an
escape platform submerged 1 cm below the water line.
The platform was kept at a constant location within the
pool during the first 3 days of training. On the morning of
the 4th day the escape platform was placed in the quad-
rant opposite to the first target quadrant to start the
reversal learning task for two more days. The first trial of
the reversal period was analyzed as "probe trial". To con-
trol for parameters that are not hippocampus-dependent
such as vision impairments, the task was afterwards
repeated with a visible platform. To evaluate learning of
the spatial location of the platform, latencies to reach the
platform (in seconds) and total length of swim path (in
pixels converted to cm) were compared between trials.
Additionally, the time spent in the target quadrant on the
probe trials was used as an indicator of targeted searching
for the platform. During the reversal learning, time spent
in quadrant 1 (location of the platform during initial
training) versus quadrant 3 (location of the platform dur-
ing reversal training) was measured.
To analyze performance in the MWM test, we per-
formed a repeated measure ANOVA test of the daily
means. Analysis of the differences between the groups in
the parameters escape latency, and distance moved per
day, using the Fisher post-hoc-test, if applicable.
To test general locomotor functions and fitness of the
animals, a rotarod was used. The mice were placed on a
slowly rotating rod (20 rpm) and a stopwatch was started.
The rod accelerated with 20 rpm. When the mice over-
balanced and touched the ground, the stopwatch stopped
automatically. Each animal performed 4 trials.
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